119 results about "Epigenetics" patented technology

The invention discloses a method for utilizing machine learning to predict a complex disease susceptibility locus. The method comprises the following steps of 1, collecting a known complex disease susceptibility locus as a positive set of a machine learning model, predicting a locus irrelevant to a complex disease according to the positive set as a negative set, and annotating an epigenetic regulation element; 2, utilizing machine learning to establish a complex disease epigenetic model; 3, predicting all loci in a whole-genome range according to the established model to obtain a final prediction result as a potential susceptibility locus of the complex disease. According to the method for utilizing machine learning to predict the complex disease susceptibility locus, epigenetic information and genome DNA information are combined, epigenetic element features are extracted through machine learning, the susceptibility locus of the complex disease is further predicted in a whole-genome range, heritability explained by the found susceptibility locus can be obviously improved, and a potential target is provided for subsequent medicine design and disease detection.

The disclosure relates to devices, solutions and methods for collecting and processing samples of bodily fluids containing cells (as well as embodiments for the collection, and processing and/or analysis of other fluids including toxic and/or hazardous substances/fluids). In addition, the disclosure relates generally to function genomic studies and to the isolation and preservation of cells from saliva and other bodily fluids (e.g., urine), for cellular analysis. With respect to devices for collection of bodily fluids, some embodiments include two mating bodies, a cap and a tube (for example), where, in some embodiments, the cap includes a closed interior space for holding a sample preservative solution and mates with the tube to constitute the (closed) sample collection device. Upon mating, the preservation solution flows into the closed interior space to preserve cells in the bodily fluid. The tube is configured to receive a donor sample of bodily fluid (e.g., saliva, urine), which can then be subjected to processing to extract a plurality of cells. The plurality of cells can be further processed to isolate one and/or another cell type therefrom. The plurality of cells, as well as the isolated cell type(s), can be analyzed for functional genomic and epigenetic studies, as well as biomarker discovery.

A construction method of a test case constraint control technology based on epigenetics includes steps of: 1: defining a fitness function, a genetic coding method, and a constraint control rule; 2: initializing parameters: setting a population size, an evolution number, and a termination fitness function value; 3: initializing a population: randomly generating an initial population; 4: performing evolution termination judgment; 5. performing constraint regulation based on the epigenetics: performing constraint methylation and constraint acetylation according to the constraint control rule; 6: selecting individuals; 7: completing epigenetic evolution of the population; and 8: outputting a test case set; wherein through the above steps, construction of an epigenetic test case constraint control technology is completed, so as to design test cases that are more in line with the actual operation conditions of the software, find more potential software failures, and improve the quality of software testing.

The invention relates to a core-shell type nano medical granule targeting to tumor cells. The core-shell type nano medical granule comprises an inner hydrophobic polymer with chemotherapeutics medicines and epigenetics medicines in an adsorbing manner, a single-layer lipid molecule layer wrapping the inner hydrophobic core, and an hydrophilic outer shell targeting to the tumor cells. The invention further relates to a preparation method of the core-shell type nano medical granule and the application of the core-shell type nano medical granule to preparing anti-tumor medicines. The core-shell type nano medical granule combines the nano wrapping, the chemotherapeutics medicines and the epigenetics medicines, thereby having the advantages of improving the medicine delivery targeting, improving the sensitivity of the tumor cells to the chemotherapeutics medicines, suppressing the medicine resistance of the tumor cells, and the like.

The invention provides a method of performing scRRBS (single-cell reduced-representation bisulfite sequencing) on an embryo culture solution. According to the method provided by the invention, medicalwaste (blastula culture solution) generated by 'test-tube baby' operation is adopted as a raw material, double analysis can be performed on the chromosome aneuploidy status and DNA methylation statusof the embryo, development potential of the embryo is evaluated from a brand new angle of epigenetics and reaction between the embryo and the culture environment, new reference is provided for selecting a 'correct' embryo in assisted reproduction, and powerful support is provided for increasing the success rate of the period of the test-tube baby.

The present invention relates to the field of epigenetics. More specifically, the present invention provides methods and compositions useful for predicting response to epigenetic drug therapy. As described herein, we have identified a unique signature termed AZA Immune gene set or AIM that differentiates patients with a low immune and high immune signature and is regulated by epigenetic drugs such as demethylating drugs, histone deacetylase inhibitors. In certain embodiments, patients with a high immune signature may benefit from immunotherapies such as anti PD1 or anti PDL1 antibodies or vaccines. In other embodiments, patients with a low immune signature or low AIM would be patients who would then benefit from treatment with epigenetic drugs and then subsequent immunotherapy.

The invention discloses recombinant fusion protein in antibody targeting and application thereof in epigenetics. The recombinant fusion protein comprises an ABP-L-DFE structure, wherein ABP is locatedin the N terminal of the recombinant fusion protein and represents a structure domain with a binding antibody function, L represents a connecting peptide, and DFE represents a structure domain with aDNA (Deoxyribonucleic Acid) fragmentation function. The recombinant fusion protein disclosed by the invention is capable of improving a ChIP-seq (Chromatin Immunoprecipitation-sequencing) technology,simplifying operation, increasing data quality, reducing operation difficulty and expanding the application range, particularly the application in a small amount of precious cells.

The invention relates to a human parthenogenetic embryo stem cell line with two active X chromosomes and derivatives thereof. A karyotype of the human parthenogenetic embryo stem cell line is 46, XX before 10 generations; the karyotype of the cell line becomes a chimera from the 20th generation; all cells of the cell line lose an active X chromosome at the 35th generation; and in the inactivation detection of the X chromosome, only the state of the active X chromosome is maintained all along, but the presence of the inactivated X chromosome is not discovered. The parthenogenetic activation can be achieved by adopting an artificial activation condition causing a second polar body to be discharged; therefore, the human parthenogenetic embryo stem cell line and the derivatives thereof can be obtained. The cell line and the derivatives thereof have important significance on researching the characteristics of the cell on genetics and epigenetics and further applying the cell to clinically treating certain diseases; and a cell source for cell replacement therapy can be obtained by transforming genes of the cell or modifying the genes on the epigenetics.

A method for determining the epigenetic age acceleration of an individual comprising measuring a methylation level of a set of methylation markers in genomic DNA of an individual. An epigenetic age of the individual is determined based on the measured methylation level. An epigenetic age of the individual is further determined based on a methylation derived weighted average cell count of naive cytotoxic T cells and exhausted cytotoxic T cells in the individual. The determined epigenetic age is then compared to a chronological age of the individual to determine an epigenetic age acceleration of the individual. Instances wherein the epigenetic age is greater than the chronological age of the individual is an indication of an increased risk of all-cause mortality.

The invention provides a fusion protein and an application thereof. Specifically, the invention provides a fusion protein, which comprises or consists of the following components: (1) a positioning functional element D1 with functions of targeting and combining DNA; and (2) a demethylated functional element D2 having a function of converting methylated nucleotides into non-methylated nucleotides. The demethylation method provided by the invention has accurate and efficient demethylation modification efficiency in plants, and has important scientific values for researching plant epigenetics and regulating plant traits through demethylation.

The invention discloses compounds for specifically and chemically marking 5-aldehyde uracil and a marking method and application. A compound 1 with an azide group can be selectively reacted with an aldehyde group of 5-aldehyde uracil, and then alkynyl-carrying biotin DBCO-S-S-PEG3-biotin is added to generate an click reaction with azide without a catalyst. By using the 5-ldehyde uracil specific chemical marking method disclosed by the invention, specific enriching of nucleic acid samples containing 5-aldehyde uracil can be realized, and the sequence distribution information of the 5-aldehyde uracil in nucleic acid molecules can be analyzed. The invention provides an effective research method for the field of epigenetics and nucleic acid chemicobiology.

karounitriol is an important active ingredient from traditional Chinese medicine material semen trichosanthis. The invention discloses a novel function of karounitriol. It is found through experiments of the action of semen trichosanthis glycol on rat primary culture nerve cells that the expression level of DNMT1 genes can be reduced by addition of karounitriol. DNMT1 is the key enzyme causing DNA methylation which is an important constituent part of epigenetics, changes of DNA methylation represent that the nervous system makes a global stress reaction on karounitriol, and it is shown that karounitriol has a significant regulating effect on activities of the nervous system.

The invention belongs to the technical field of the biology, and relates to a method for regulating the growth of plants and an application thereof, in particular to an application of paddy rice Histone-lysine methyltransferase gene which is associated to the Epigenetics in the regulation of the plant growth. The name of the gene is SDG714, and the accession number is NM_001051801. Through a designed primer, a target gene entering plant expression carrier is obtained, and the plant Arabidopsis is transformed in an Agrobacterium rhizogenes medium transformation mode. Compared with a contrast group, in the plant of the over-expression SDG714, the methylation level of the histone H3K9 is obviously improved to cause the decrease of a great amount of genes which are related to the growth of the plant and to seriously inhibit the growth of the Arabidopsis; and once the SDG714 which is over-expressed is removed in the plant with the growth being inhibited, the plant can continue to grow. The method for regulating the growth of the plant has high real application value and promising application prospect.

The invention relates to an efficient and fast detection method of integral DNA methylation level. The invention realizes separation and detection of a DNA-antibody immune compound by an immune capillary electrophoresis-laser induced fluorescence technology to quantitatively analyze the integral methylation level in the DNAs to be detected. Compared with the traditional detection method of the integral DNA methylation level, the method requires no the steps such as bisulfite treatment, DNA enzymolysis, PCR amplification and the like, and has the advantages of simple and fast operation, a smallquantity of the DNAs, high detection sensitivity and the like, thus realizing efficient and fast detection of the integral DNA methylation level; and the method is applicable to detection of variousbiological samples, fast screening of influence of environmental pollutants on DNA methylation and epigenetics evaluation on diseases such as cancer and the like.

The present invention relates to a method for assisting in diagnosing breast cancer and/or monitoring breast cancer progression in a given sample based on the analysis of differential DNA methylation patterns. More particularly, the method is directed to the identification of one or more epigenetic markers that derive from the application of a variety of statistical methods in order to point out the prognostic significance of the difference in methylation states at one or more genomic loci and predict whether the sample analyzed has a good or bad prognosis following treatment.

The invention relates to a method for parsing the blastocyst ectoderm cell DNA methylation status by means of a phenogenetics analysis technology by taking 'test tube baby' blastocyst ectoderm cells as raw materials and adopting a double-enzyme digestion single-cell reduced-representation bifulfite sequencing technology and conducting preimplantation genetic screening on the chromosome state. Thedevelopment potential of an embryo is comprehensively evaluated from various angles, a new reference is provided for selecting the 'right' embryo in assisted reproduction, and strong support is provided for increasing the success rate of the 'test-tube baby' cycle.

The invention relates to applications of a transcription factor CREB in JHDM2A gene expression regulation and pig lipid deposition reduction. By overexpression of CREB in pigs, or by improvement of the CREB phosphorylation level in pigs, or by promotion of combination of pig CBP protein and the phosphorylated CREB, JHDM2A gene expression in pigs is up-regulated, thus regulating lipid metabolism pathways from the epigenetics and reducing pig lipid deposition. Novel applications of the transcription factor CREB in the epigenetics are provided for the first time and the transcription factor CREB can be used for reducing pig lipid deposition, namely, expression of the histone demethylase JHDM2a is directly activated so that the histone demethylase JHDM2a can regulate the lipid metabolism pathways from the epigenetics, thus minifying lipid cells and increasing the meat factor. A novel candidate gene is provided for genetic breeding, meat quality improvement, and the like in the animal husbandry.

The invention provides a method for breeding a novel cockscomb specie by epigenetics principle and distant hybridization. The method comprises the following steps of a, carrying out distant hybirdization on a coronary cultivated specie and feather cockscomb and carrying out hormone treatment to obtain filial generation F1-1, b, carrying out hybridization on the coronary cultivated specie and Vietnam red to obtain filial generation F1-2, c, compounding the filial generation F1-1 and F1-2 to obtain filial generation CCF1, d, carrying out backcrossing on the CCF1 and the coronary cultivated cockscomb specie, e, controlling growth of cockscomb plants with spicate, coronary and phoenix tail-shaped inflorescences according to difference of a temperature and illumination, selecting hybrid filial generation and carrying out directional cultivation, and f, carrying out cultivation for 5 generations to obtain the novel cockscomb specie simultaneously with spicate, coronary and phoenix tail-shaped inflorescences. The method can breed the novel ornamental cockscomb specie with multiple types of inflorescences.

A transgenic fly whose genome is modified to express enhanced levels of glutamate-cysteine ligase (GCL) gene is provided. The fly displays phenotypes associated with Alzheimer's disease (AD). Further, a method for diagnosing AD is provided, which includes assessing enzymatic activities in mitochondrial enzymes. Glutathione pathway are investigated by creating Alzheimer's model Drosophila with over-expression of the GCLc gene, inducing redox stress through sleep deprivation, and analyzing mitochondrial electron transport chain (ETC) using colorimetric enzymatic assays. For prevention of AD, it is proposed that the epigenetic approaches be used to increase glutathione levels in vivo before the onset of AD. For treatment of AD, it is proposed that the glutathione levels be increased by GCLc modulation.